Medtronic (MDT) and DaVita (DVA) to Form new Independent Kidney Technology Company

Go back to Medtronic (MDT) and DaVita (DVA) to Form new Independent Kidney Technology Company

Medtronic, Inc. (MDT) PT Lowered to $111 at Truist Securities

May 27, 2022 8:09 AM EDT

Truist Securities analyst Richard Newitter lowered the price target on Medtronic, Inc. (NYSE: MDT) to $111.00 (from $121.00) while maintaining a Hold rating following earnings.

The analyst commented, "We stay at HOLD following MDT's disappointing F4Q & below CNS F1Q/FY23 guide. We appreciate MDT's... More

Medtronic, Inc. (MDT) PT Lowered to $117 at Cowen; FY23 Can Be a Year of Real Pipeline Progress

May 27, 2022 6:21 AM EDT

Cowen analyst Joshua Jennings lowered the price target on Medtronic, Inc. (NYSE: MDT) to $117.00 (from $125.00) while maintaining an Outperform rating following earnings. Despite weak guidance, the analyst said FY23 can be a year of real pipeline progress.

The analyst commented, "MDT delivered... More